These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 18304612

  • 21. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ.
    Aliment Pharmacol Ther; 2008 Nov 01; 28(9):1122-6. PubMed ID: 18691349
    [Abstract] [Full Text] [Related]

  • 23. Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease.
    Misago N, Narisawa Y.
    Am J Dermatopathol; 2012 May 01; 34(3):325-9. PubMed ID: 22172959
    [Abstract] [Full Text] [Related]

  • 24. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
    Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr 01; 10(2):163-75. PubMed ID: 20384563
    [Abstract] [Full Text] [Related]

  • 25. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A.
    Tunis Med; 2012 Feb 01; 90(2):101-7. PubMed ID: 22407620
    [Abstract] [Full Text] [Related]

  • 26. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.
    Scand J Gastroenterol; 2012 May 01; 47(5):528-37. PubMed ID: 22356594
    [Abstract] [Full Text] [Related]

  • 27. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F, Giudici F, Asteria CR.
    Dis Colon Rectum; 2012 Aug 01; 55(8):870-5. PubMed ID: 22810472
    [Abstract] [Full Text] [Related]

  • 29. [Metastatic Crohn's disease. Response to adalimumab dose intensification].
    Lázaro Saéz M, Hernández Martínez A, Bendezú García RÁ, Rodríguez Manrique MA, Simón López F, Medina Estévez E, Vega Sáenz JL.
    Gastroenterol Hepatol; 2012 May 01; 35(5):321-5. PubMed ID: 22445940
    [Abstract] [Full Text] [Related]

  • 30. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M.
    Dermatology; 2007 May 01; 215(4):295-300. PubMed ID: 17911986
    [Abstract] [Full Text] [Related]

  • 31. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
    Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD.
    Gut; 2004 Sep 01; 53(9):1295-302. PubMed ID: 15306588
    [Abstract] [Full Text] [Related]

  • 32. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 01; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

  • 33. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 34. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C.
    Clin Pharmacol Ther; 2008 Jan 01; 83(1):70-6. PubMed ID: 17507924
    [Abstract] [Full Text] [Related]

  • 35. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.
    Gastroenterology; 2006 Feb 01; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [Abstract] [Full Text] [Related]

  • 36. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR.
    Gastroenterol Clin North Am; 2006 Dec 01; 35(4):795-820. PubMed ID: 17129814
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Gastrocnemius Myalgia as a Rare Initial Manifestation of Crohn's Disease.
    Osada A, Yamada H, Takehara S, Tozuka Y, Fukushima T, Oka H, Okazaki H, Nagaoka S.
    Intern Med; 2018 Jul 15; 57(14):2001-2006. PubMed ID: 29491286
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.